Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
PharvarisN. V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases.
The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE).
It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
The company operates in the Netherlands, Switzerland, and the United States.
PharvarisN. V. was incorporated in 2015 and is based in Leiden, the Netherlands.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 7, 25 | -0.68 Decreased by -31.29% | - |
| Dec 31, 24 | -0.64 Increased by +21.95% | -0.73 Increased by +11.91% |
| Nov 14, 24 | -0.77 Decreased by -32.76% | -0.60 Decreased by -27.42% |
| Aug 5, 24 | -0.60 Increased by +4.76% | -0.58 Decreased by -3.45% |
| May 8, 24 | -0.52 Increased by +55.56% | -0.56 Increased by +7.14% |
| Mar 6, 24 | -0.82 Increased by +34.40% | -0.58 Decreased by -41.38% |
| Nov 2, 23 | -0.58 Decreased by -132.00% | -0.60 Increased by +3.33% |
| Aug 7, 23 | -0.63 Decreased by -65.79% | -0.65 Increased by +3.08% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | N/A Decreased by N/A% | -34.76 M Decreased by -24.06% | - - |
| Dec 31, 24 | 0.00 Decreased by N/A% | -34.76 M Decreased by -6.15% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -41.71 M Decreased by -76.75% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -29.73 M Decreased by -4.16 K% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -28.02 M Decreased by -23.81% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -32.75 M Increased by +16.45% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -23.60 M Decreased by -178.03% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | 733.08 K Increased by +105.81% | Increased by +N/A% Decreased by N/A% |